Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine

• US 9,212,183 B2
• Filed: 05/09/2014
• Issued: 12/15/2015
• Est. Priority Date: 12/23/2008
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Sieger, Peter, Pfrengle, Waldemar
• Primary Examiner(s): Murray, Jeffrey H
• Application Number:
  US14/273,753
• Publication Number:
  US 20140303194A1
• Time in Patent Office: 585 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/194 having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07C 309/04 containing only one sulfo group
• CPC Class Codes: C07C 309/29 : of non-condensed six-membered aromatic rings
• CPC Class Codes: C07C 59/06 : Glycolic acid
• CPC Class Codes: C07C 59/235 : Saturated compounds containing more than one carboxyl group
• CPC Class Codes: C07C 63/08 : Salts thereof
• CPC Class Codes: C07C 65/05 : o-Hydroxy carboxylic acids
• CPC Class Codes: C07C 65/10 : Salicylic acid
• CPC Class Codes: C07D 473/04 : two oxygen atoms

Abstract

The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, processes for making these novel salts, and pharmaceutical compositions comprising such novel salts. The invention also relates to the use of these novel salts in the treatment of type 2 diabetes.

Claims

1. A solid crystalline acid addition salt of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine with gentisic acid;

wherein the molar ratio of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine to gentisic acid in said acid addition salt is substantially 1;

1.

2. The salt according to claim 1,

having characteristic X-ray reflections (2Θ

) of 4.06, 9.69, 11.72, 23.85, and 11.30°

.

3. A pharmaceutical composition comprising a salt according to claim 1, optionally together with one or more pharmaceutically acceptable carriers and/or diluents.

4. The pharmaceutical composition according to claim 3, further comprising one or more other active substances.